Compuesto Regulado por la FDA
Este compuesto es aprobado o regulado por la FDA. Comprar sin una receta válida puede violar la ley federal. Verifica todos los requisitos legales en tu jurisdicción.
Semaglutide
Ozempic / Wegovy / Rybelsus
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.
Mecanismo de Acción
GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.
Protocolos de Investigación
Para propósitos de investigación solo. No es asesoramiento médico.
Typical research protocols use 0.25mg weekly for 4 weeks, escalating to 0.5mg weekly, then 1mg weekly. Maximum studied dose is 2.4mg weekly for weight management.
Notas de Investigación
Clinical Research Status
FDA-approved for type 2 diabetes (Ozempic 2017, Rybelsus 2019) and obesity (Wegovy 2021). Ongoing Phase 3 trials for NASH/MASH (liver disease), heart failure with preserved ejection fraction, Alzheimer's disease, and substance use disorders. SELECT trial demonstrated 20% cardiovascular risk reduction in overweight patients.
Key Published Findings
STEP trials demonstrated 15-17% average body weight loss over 68 weeks at 2.4mg weekly dose. SUSTAIN trials showed HbA1c reductions of 1.5-1.8% in type 2 diabetes. PIONEER trials established efficacy of oral formulation. FLOW trial showed 24% reduction in kidney disease progression. STEP HFpEF trial showed significant improvement in heart failure symptoms and physical limitations.
Safety Profile
Most common side effects are gastrointestinal: nausea (40-44%), diarrhea (30%), vomiting (24%), constipation (24%). These typically diminish with dose titration. Black box warning for thyroid C-cell tumors (observed in rodents, not confirmed in humans). Reports of pancreatitis, gallbladder events, and retinopathy complications. Post-marketing reports of suicidal ideation under investigation.
Drug Interactions & Contraindications
Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Delays gastric emptying, which may affect absorption of other oral medications. Caution with insulin or sulfonylureas (increased hypoglycemia risk). Not recommended during pregnancy or breastfeeding.
Comparison to Related Compounds
More potent and longer-acting than liraglutide (Victoza/Saxenda). Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist showing slightly greater weight loss (up to 22.5% in SURMOUNT trials). Retatrutide (triple agonist) in Phase 3 trials shows even greater efficacy. CagriSema (semaglutide + cagrilintide) in Phase 3 trials combines GLP-1 and amylin pathways.
Community Observations
Extreme demand has led to widespread shortages and compounding pharmacy versions of varying quality. Counterfeit products are a significant concern. Users commonly report dramatic appetite suppression, food noise reduction, and altered relationship with alcohol. Muscle loss during weight loss is a frequently discussed concern — resistance training and adequate protein intake are widely recommended.
Media Vida
~7 days
Reconstitución
Bacteriostatic water (BAC)
Almacenamiento
Liofilizado
Room temperature up to 36 months. Protect from light.
Reconstituído
Refrigerate 2-8C. Use within 56 days.
Estado Legal EE.UU.
También Se Conoce Como
Última Investigación
Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
Preguntas frecuentes
¿Qué es Semaglutide?
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.
¿Cómo funciona Semaglutide?
GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.
¿Cuál es el estado regulatorio de Semaglutide en EE. UU.?
FDA-approved (Rx only)
¿Cuál es la vida media de Semaglutide?
~7 days
¿Qué otros nombres tiene Semaglutide?
Ozempic, Wegovy, Rybelsus
Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.
Leer aviso completo